कंपनी लोड हो रही है
Beone Medicines Ltd.
ONC · Nasdaq · ·
$416.41+0.1%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 5 नवंबर 2026 को दाखिल 10-Q से
पिछला प्रदर्शन
- 1W
- +2.3%
- 1M
- +11.3%
ONC · Nasdaq · ·
$416.41+0.1%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 5 नवंबर 2026 को दाखिल 10-Q से
Just reported
From Beone Medicines's results release of 5 नवंबर 2026; its quarterly report has since been filed.
Actual
$1.89B
+34% y/y
+11% q/q
Guided
—
No guide given
Actual
$3.25
+213% y/y
+56% q/q
Guided
—
No guide given
Actual
$418.7M
+157% y/y
+29% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
TGTXTG Therapeutics, Inc.$9.7BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now Aआमदनी के हिस्से Q1 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.
XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.
BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.
Beone Medicines Ltd. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
BeOne Medicines sells cancer medicines, chiefly BRUKINSA pills for blood cancers, to patients and health systems worldwide.
कंपनी का अनुमान: वित्त वर्ष 2026 के लिए $6.9B से $7B का राजस्व — एक साल पहले से 30.1% अधिक
Grade A+
भाव के नीचे की पट्टी हर तारीख की ग्रेड दिखाती है, जो सिर्फ़ उस समय तक सार्वजनिक दस्तावेज़ों से बनी है।
Beone Medicines Ltd. के ग्रेड इतिहास की 40 तिमाहियों में से 2 दिखाई जा रही हैं। बाकी 38 मार्च 2017 तक जाती हैं।